close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

122.81 +4.96 (+4.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
65 66 Next >
FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment
The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment,  
Via Benzinga
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
This Is What Whales Are Betting On Gilead Sciences
 
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
 
Via Benzinga
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
From Gilead Sciences, Inc.
Via Business Wire
7 Tech Stocks to Watch on July 14
Tech stocks are on the rise today ahead of the upcoming Nasdaq 100 rebalancing, the changes for which will be announced this Friday, July 14. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Nasdaq 100 Index Shake-Up Rattles High-Flying Stocks of 2023
The Nasdaq 100 index is set for a special rebalancing. Seven mega-cap stocks driving the market's gains, as well as other stocks, face weighting adjustments. 
Via MarketBeat
Gilead Sciences' Debt Overview
 
Via Benzinga
Ominous Death Cross Forms On Gilead Sciences's Chart
 
Via Benzinga
Expert Ratings for Gilead Sciences
 
Via Benzinga
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Read the latest report on NanoViricides here. 
Via Benzinga
Is Johnson & Johnson Stock a Buy Now?
Some businesses never go out of style. 
Via The Motley Fool
$1 Billion Deal For Moderna To Expand Product Pipeline in China
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher 
Via MarketBeat
Topics ETFs Economy
The 3 Best Biotech Stocks to Buy In July
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Read the latest report on NanoViricides here. 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
 
Via Benzinga
Inflammatory Bowel Disease Market expected to rise | Companies – Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market
Via AB Newswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Amgen Inc. Dividend Stock Analysis
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
Primary Sclerosing Cholangitis Market expected to rise | Companies – Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics
Via AB Newswire
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t 
Via MarketBeat
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows 
Via News Direct
Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years
Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for  
Via Benzinga
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
From Gilead Sciences, Inc.
Via Business Wire
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today